168 results on '"Daniels, Molly S."'
Search Results
2. Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome
3. Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort
4. Data from Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome
5. Commentary on This Article from Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome
6. Data from Microscopic and Early-Stage Ovarian Cancers in BRCA1/2 Mutation Carriers: Building a Model for Early BRCA-Associated Tumorigenesis
7. Supplementary Table 1 from Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome
8. Supplementary Figure Legend from Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome
9. Supplementary Table S1 from Microscopic and Early-Stage Ovarian Cancers in BRCA1/2 Mutation Carriers: Building a Model for Early BRCA-Associated Tumorigenesis
10. Supplementary Figure 1 from Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome
11. Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for lynch syndrome
12. Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers
13. Outcomes of screening endometrial cancer patients for Lynch syndrome by patient-administered checklist
14. Is low-grade serous ovarian cancer part of the tumor spectrum of Hereditary Breast and Ovarian Cancer?
15. Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas
16. A clinical perspective on genetic counseling and testing during end of life care for women with recurrent progressive ovarian cancer: opportunities and challenges
17. Genetic Counseling Considerations in the Evaluation of Families for Lynch Syndrome—A Review
18. Obstetrics/Gynecology Residents’ Knowledge of Hereditary Breast and Ovarian Cancer and Lynch Syndrome
19. Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer
20. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome
21. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma
22. Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers
23. Expanded Analysis of Secondary Germline Findings From Matched Tumor/Normal Sequencing Identifies Additional Clinically Significant Mutations
24. Cost-Effectiveness Analysis of Prevention Strategies for Gynecologic Cancers in Lynch Syndrome
25. Pathologic features of endometrial carcinoma associated with HNPCC: A comparison with sporadic endometrial carcinoma
26. Women With Synchronous Primary Cancers of the Endometrium and Ovary: Do They Have Lynch Syndrome?
27. Real-world outcomes of genetic testing in a GU genetics clinic and evaluation of current guidelines.
28. Disclosure of secondary germline findings from clinical tumor-normal paired somatic mutation profiling.
29. Frequency of Germline BRCA1/2 Mutations in Unselected Patients With Colorectal Cancer
30. Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors.
31. Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors.
32. Evaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes.
33. Genetic predisposition in gynecologic cancers
34. Satisfaction with Ovarian Carcinoma Risk-Reduction Strategies Among Women at High Risk for Breast and Ovarian Carcinoma
35. Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program.
36. Clearer Picture of PMS2-Associated Lynch Syndrome Is Emerging
37. Reply to D. Braun et al
38. A prospective evaluation of universal tumor testing strategies for Lynch syndrome in endometrial cancer.
39. Underestimation of Risk of a BRCA1 or BRCA2 Mutation in Women With High-Grade Serous Ovarian Cancer by BRCAPRO: A Multi-Institution Study
40. Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas
41. Genetic Testing by Cancer Site
42. Lifetime Cancer Risks of PTEN Mutation Carriers—Letter
43. An alternative approach to identify women at risk for colorectal cancer.
44. A multi-institution study of the accuracy of BRCAPRO in predicting BRCA1/BRCA2 mutations in women with ovarian cancer.
45. Risk-reducing salpingo-oophorectomy and prophylactic mastectomy among BRCA mutation “previvors.”
46. Abstract B29: Screening and communication with physicians for women with Lynch syndrome: Findings from a qualitative study
47. Testing Women With Endometrial Cancer to Detect Lynch Syndrome
48. Microscopic and Early-Stage Ovarian Cancers in BRCA1/2 Mutation Carriers: Building a Model for Early BRCA-Associated Tumorigenesis
49. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma
50. Expanding the Criteria for BRCA Mutation Testing in Breast Cancer Survivors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.